FDA Pregnancy Registry Guidance Should Stratify Drugs By Prevalence Of Use
Stratification of drugs according to prevalence of use in women of childbearing potential would assist industry in determining when pregnancy registries should be established, FDA's Reproductive Health Drugs Advisory Committee agreed at its Oct. 18 meeting.
You may also be interested in...
FDA should document the historical usefulness of pregnancy registry data to product labeling decisions before proceeding with its recently released pregnancy registry draft guidances, the Pharmaceutical Research & Manufacturers of America said in Aug. 31 comments to the agency.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials